BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34810212)

  • 1. Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.
    Shen C; Shyu DL; Xu M; Yang L; Webb A; Duan W; Williams TM
    Mol Cancer Res; 2022 Mar; 20(3):425-433. PubMed ID: 34810212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
    Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
    Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
    Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.
    Quintanal-Villalonga A; Taniguchi H; Zhan YA; Hasan MM; Chavan SS; Meng F; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Ciampricotti M; Chow A; Offin M; Ray-Kirton J; Egger JD; Bhanot UK; Linkov I; Asher M; Roehrl MH; Ventura K; Qiu J; de Stanchina E; Chang JC; Rekhtman N; Houck-Loomis B; Koche RP; Yu HA; Sen T; Rudin CM
    J Hematol Oncol; 2021 Oct; 14(1):170. PubMed ID: 34656143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
    Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
    Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells.
    Wang R; Li A; Liu J; Fang M; Zhu Y; Huang J; Liu Y; Huo L; You Q
    J Chemother; 2023 Apr; 35(2):95-103. PubMed ID: 35238281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
    Wang H; Zhang Y; Tian Y; Yang W; Wang Y; Hou H; Pan H; Pei S; Zhu H; Gu Z; Zhang Y; Dai D; Chen W; Zheng M; Luo Q; Xiao Y; Huang J
    Cancer Res; 2024 Mar; 84(5):688-702. PubMed ID: 38199791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin enhances cisplatin sensitivity of resistant non-small cell lung carcinoma stem-like cells by targeting mTOR-Akt axis to repress migration.
    Khan P; Bhattacharya A; Sengupta D; Banerjee S; Adhikary A; Das T
    Sci Rep; 2019 Nov; 9(1):16913. PubMed ID: 31729456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
    Feng FF; Cheng P; Sun C; Wang H; Wang W
    Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of lysine (K)-specific demethylase 2B KDM2B inhibits glycolysis and induces autophagy in lung squamous cell carcinoma cells by regulating the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.
    Xie Z; Li H; Zang J
    Bioengineered; 2021 Dec; 12(2):12227-12235. PubMed ID: 34783291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.